Delaware
|
|
001-39388
|
|
35-2415390
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
5858 Horton Street, Suite 320
Emeryville CA
|
|
94608
|
(Address of principal executive offices)
|
|
(Zip Code)
|
☒
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock, par value $0.00005 per share
|
|
BLI
|
|
The Nasdaq Global Select Market
|
Item 8.01
|
Other Events |
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
99.1
|
Unaudited pro forma condensed combined financial information of Berkeley Lights, Inc. giving effect to the acquisition of IsoPlexis Corporation, which includes the unaudited pro forma condensed combined balance sheet as of December 31, 2022, the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022, and the notes related thereto.
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Date: March 6, 2023
|
Berkeley Lights, Inc.
|
|
By:
|
/s/ Scott Chaplin |
|
|
|
Name: |
Scott Chaplin |
|
|
Title: |
Chief Legal Officer |
(1) |
the Berkeley Lights historical audited consolidated statement of operations for the year ended December 31, 2022; and
|
(2) |
the IsoPlexis historical audited consolidated statement of operations for the year ended December 31, 2022.
|
(1) |
the Berkeley Lights historical audited consolidated balance sheet as of December 31, 2022; and
|
(2) |
the IsoPlexis historical audited consolidated balance sheet as of December 31, 2022.
|
(1) |
Berkeley Lights’ Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 23, 2023;
|
(2) |
IsoPlexis’ Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023.
|
(In thousands, except share and per share data)
|
Historical
Berkeley
Lights, Inc.
|
Historical
IsoPlexis
Corporation
After
Reclassifications
(Note 4)
|
Pro Forma Transaction Adjustments
(Note 6)
|
Notes
(Note 6)
|
Pro Forma Combined Company
|
Revenue:
|
|||||
Product revenue
|
$48,930
|
$13,852
|
$—
|
$62,782
|
|
Service revenue
|
29,665
|
2,909
|
—
|
32,574
|
|
Total revenue
|
78,595
|
16,761
|
—
|
95,356
|
|
Cost of sales:
|
|||||
Product cost of sales
|
14,261
|
17,453
|
7,501
|
(a), (b),(c)
|
39,215
|
Service cost of sales
|
10,553
|
233
|
—
|
10,786
|
|
Total cost of sales
|
24,814
|
17,686
|
7,501
|
50,001
|
|
Gross profit
|
53,781
|
(925)
|
(7,501)
|
45,355
|
|
Operating expenses:
|
|||||
Research and development
|
53,207
|
23,504
|
3,480
|
(c)
|
80,191
|
Selling, general and administrative
|
95,115
|
72,556
|
(2,749)
|
(a), (c), (d)
|
164,922
|
Restructuring
|
3,513
|
4,245
|
—
|
7,758
|
|
Total operating expenses
|
151,835
|
100,305
|
731
|
252,871
|
|
Loss from operations
|
(98,054)
|
(101,230)
|
(8,232)
|
(207,516)
|
|
Other income (expense):
|
|||||
Interest expense
|
(910)
|
(5,342)
|
—
|
(6,252)
|
|
Interest income
|
1,270
|
50
|
—
|
1,320
|
|
Other income (expense), net
|
(246)
|
525
|
—
|
279
|
|
Loss before income taxes
|
(97,940)
|
(105,997)
|
(8,232)
|
(212,169)
|
|
Provision for income taxes
|
100
|
—
|
—
|
(e)
|
100
|
Net loss
|
$(98,040)
|
$(105,997)
|
$(8,232)
|
$(212,269)
|
|
Net loss attributable to common stockholders per share, basic and diluted
|
$(1.42)
|
$(2.28)
|
|||
Weighted-average shares used in calculating net loss per share, basic and diluted
|
68,865,596
|
24,335,018
|
(f)
|
93,200,614
|
(In thousands, except share and per share data)
|
Historical
Berkeley
Lights, Inc.
|
Historical
IsoPlexis
Corporation
After
Reclassification
(Note 4)
|
Pro Forma Transaction Adjustments
(Note 7)
|
Notes
(Note 7)
|
Pro Forma
Combined
Company
|
Assets
|
|||||
Current assets:
|
|||||
Cash and cash equivalents
|
$86,522
|
$37,465
|
$(13,000)
|
(g)
|
$110,987
|
Short-term marketable securities
|
46,252
|
—
|
—
|
46,252
|
|
Trade accounts receivable
|
18,534
|
4,502
|
—
|
23,036
|
|
Inventory
|
18,861
|
27,516
|
4,863
|
(h)
|
51,240
|
Prepaid expenses and other current assets
|
6,783
|
2,382
|
—
|
9,165
|
|
Total current assets
|
176,952
|
71,865
|
(8,137)
|
240,680
|
|
Property and equipment, net
|
23,847
|
11,237
|
—
|
35,084
|
|
Intangible assets, net
|
—
|
19,824
|
(1,525)
|
(j)
|
18,299
|
Operating lease right-of-use assets
|
23,326
|
5,068
|
—
|
28,394
|
|
Other assets
|
1,969
|
1,074
|
—
|
3,043
|
|
Total assets
|
$226,094
|
$109,068
|
$(9,662)
|
$325,500
|
|
Liabilities and Stockholders’ Equity
|
|||||
Current liabilities:
|
|||||
Trade accounts payable
|
$10,092
|
$2,782
|
—
|
|
$12,874
|
Accrued expenses and other current liabilities
|
21,340
|
13,495
|
$(9,500)
|
(k) |
25,335
|
Current portion of notes payable
|
4,966
|
—
|
—
|
4,966
|
|
Deferred revenue
|
9,092
|
1,434
|
—
|
10,526
|
|
Total current liabilities
|
45,490
|
17,711
|
(9,500)
|
53,701
|
|
Notes payable
|
14,860
|
46,355
|
3,645
|
(l)
|
64,860
|
Deferred revenue, net of current portion
|
963
|
—
|
—
|
963
|
|
Lease liability, long-term
|
22,726
|
3,735
|
—
|
26,461
|
|
Total liabilities
|
84,039
|
67,801
|
(5,855)
|
145,985
|
|
Commitments and contingencies
|
|||||
Stockholders’ equity:
|
|||||
Common stock
|
4
|
40
|
(39)
|
(m)
|
5
|
Additional paid-in capital
|
503,708
|
281,203
|
(240,244)
|
(m)
|
544,667
|
Accumulated deficit
|
(361,648)
|
(239,970)
|
236,470
|
(m)
|
(365,148)
|
Accumulated other comprehensive loss
|
(9)
|
(6)
|
6
|
(m)
|
(9)
|
Total stockholders’ equity
|
142,055
|
41,267
|
(3,807)
|
(m)
|
179,515
|
Total liabilities and stockholders’ equity
|
$226,094
|
$109,068
|
$(9,662)
|
$325,500
|
(In thousands)
|
Historical IsoPlexis Corporation
Before
Reclassifications
|
Reclassifications
|
Notes
|
Historical
IsoPlexis
Corporation
After
Reclassifications
|
Revenue:
|
||||
Product revenue
|
$13,852
|
$—
|
$13,852
|
|
Service revenue
|
2,909
|
—
|
2,909
|
|
Total revenue
|
16,761
|
—
|
16,761
|
|
Cost of sales:
|
||||
Product cost of sales
|
17,453
|
—
|
17,453
|
|
Service cost of sales
|
233
|
—
|
233
|
|
Total cost of sales
|
17,686
|
—
|
17,686
|
|
Gross profit
|
(925)
|
—
|
(925)
|
|
Operating expenses:
|
||||
Research and development
|
23,504
|
—
|
23,504
|
|
General and administrative expenses
|
42,680
|
(42,680)
|
i
|
—
|
Sales and marketing expenses
|
29,876
|
(29,876)
|
i
|
—
|
Selling, general and administrative
|
—
|
72,556
|
i
|
72,556
|
Restructuring
|
4,245
|
—
|
4,245
|
|
Total operating expenses
|
100,305
|
—
|
100,305
|
|
Loss from operations
|
(101,230)
|
—
|
(101,230)
|
|
Other income (expense):
|
||||
Interest expense
|
(5,342)
|
—
|
(5,342)
|
|
Interest income
|
—
|
50
|
ii
|
50
|
Other expense, net
|
575
|
(50)
|
ii
|
525
|
Loss before income taxes
|
(105,997)
|
—
|
(105,997)
|
|
Provision for income taxes
|
—
|
—
|
—
|
|
Net loss
|
$(105,997)
|
$—
|
$(105,997)
|
i. |
Represents reclassification of general and administrative and sales and marketing expenses to selling, general and administrative expenses.
|
ii. |
Represents reclassification of interest income from other expense, net to interest income.
|
(In thousands)
|
Historical IsoPlexis Corporation Before Reclassifications
|
Reclassifications
|
Notes
|
Historical IsoPlexis Corporation After Reclassifications
|
Assets
|
||||
Current assets:
|
||||
Cash and cash equivalents
|
$37,465
|
$—
|
$37,465
|
|
Short-term marketable securities
|
—
|
—
|
—
|
|
Trade accounts receivable
|
4,502
|
—
|
4,502
|
|
Inventory
|
27,516
|
—
|
27,516
|
|
Prepaid expenses and other current assets
|
2,382
|
—
|
2,382
|
|
Total current assets
|
71,865
|
—
|
71,865
|
|
Property and equipment, net
|
11,237
|
—
|
11,237
|
|
Intangible assets, net
|
19,824
|
—
|
19,824
|
|
Operating lease right-of-use assets
|
5,068
|
—
|
5,068
|
|
Other assets
|
1,074
|
—
|
1,074
|
|
Total assets
|
$109,068
|
$—
|
$109,068
|
|
Liabilities and Stockholders’ Equity
|
||||
Current liabilities:
|
||||
Trade accounts payable
|
$2,782
|
$—
|
$2,782
|
|
Accrued expenses and other current liabilities
|
13,495
|
—
|
13,495
|
|
Current portion of notes payable
|
—
|
—
|
—
|
|
Deferred revenue
|
1,434
|
—
|
1,434
|
|
Total current liabilities
|
17,711
|
—
|
17,711
|
|
Notes payable
|
—
|
46,355
|
i
|
46,355
|
Long-term debt
|
46,355
|
(46,355)
|
i
|
—
|
Deferred revenue, net of current portion
|
—
|
—
|
—
|
|
Lease liability, long term
|
—
|
3,735
|
ii
|
3,735
|
Long-term operating lease obligations
|
3,735
|
(3,735)
|
ii
|
—
|
Total liabilities
|
67,801
|
—
|
67,801
|
|
Commitments and contingencies
|
||||
Stockholders’ equity:
|
||||
Common stock
|
40
|
—
|
40
|
|
Additional paid-in capital
|
281,203
|
—
|
281,203
|
|
Accumulated deficit
|
(239,970)
|
—
|
(239,970)
|
|
Accumulated other comprehensive loss
|
(6)
|
—
|
(6)
|
|
Total stockholders’ equity
|
41,267
|
—
|
41,267
|
|
Total liabilities and stockholders’ equity
|
$109,068
|
$—
|
$109,068
|
i. |
Represents reclassification of long-term debt to notes payable.
|
ii. |
Represents reclassification of long-term operating lease obligations to lease liability, long term.
|
(i) |
the closing price per Berkeley Lights common share on February 27, 2023, multiplied by 24.3 million Berkeley Lights common shares (the estimated number of shares that will be issued to IsoPlexis stockholders in connection with the merger, based on the 0.6120 exchange ratio and the 39.8 million shares of IsoPlexis common stock outstanding as of February 27, 2023);
|
(ii) |
the fair value attributable to an outstanding warrant for shares of IsoPlexis common stock
|
(iii) |
the portion of the fair value attributable to pre-merger completion of service with respect to outstanding equity awards held by IsoPlexis employees that will be converted into awards with
respect to Berkeley Lights common shares; and
|
(iv) |
the estimated cash consideration payable in lieu of fractional shares owed to current IsoPlexis common stockholders, which amount is not material.
|
(In millions, except per share amounts)
|
Amount
|
|
Number of shares of IsoPlexis common stock outstanding as of February 27, 2023
|
$39,763,101
|
|
Exchange ratio (1)
|
0.6120
|
|
Berkeley Lights common shares issued for IsoPlexis outstanding common stock
|
24,335,018
|
|
Closing price of Berkeley Lights common share as of February 27, 2023
|
1.64
|
|
Fair value of Berkeley Lights common shares issues for IsoPlexis common stock
|
$39,909,430
|
|
Fair value of vested IsoPlexis options estimated to be converted as of February 27, 2023 (2)
|
791,317
|
|
Fair value of IsoPlexis warrant as of February 27, 2023
|
259,640
|
|
Total estimated transaction consideration
|
$40,960,387
|
(In thousands)
|
Amount
|
|
Cash and cash equivalents
|
$37,465
|
|
Trade accounts receivable
|
4,502
|
|
Inventory
|
32,379
|
|
Prepaid expenses and other current assets
|
2,382
|
|
Property and equipment, net
|
11,237
|
|
Intangible assets subject to amortization
|
18,299
|
|
Operating lease right-of-use assets
|
5,068
|
|
Other assets
|
1,074
|
|
Trade accounts payable
|
(2,782)
|
|
Accrued expenses and other current liabilities
|
(13,495)
|
|
Deferred revenue
|
(1,434)
|
|
Notes payable
|
(50,000)
|
|
Lease liability, long-term
|
(3,735)
|
|
Total Consideration
|
$40,960
|
a. |
Amortization—Represents adjustments comprised of the following reduced amortization expense following the reduction in intangibles discussed in adjustment (j) below:
|
(In thousands)
|
Year Ended December 31, 2022
|
||
Amortization reduction in cost of goods sold
|
$(20)
|
||
Amortization reduction in general and administrative expense
|
$(110)
|
b. |
Product cost of sales—Adjustment to the year ended December 31, 2022 statement of operations related to the fair value adjustment to step-up IsoPlexis’ finished goods inventory by $4.9 million as the inventory step-up increases cost of good sold when the acquired inventory is sold after the merger.
This adjustment assumes all stepped-up inventory is sold within one year.
|
c. |
Allocation methodology—As noted above, in preparing the pro-forma combined financial statements, information was gathered through discussions with IsoPlexis’
management, due diligence information, and information presented in IsoPlexis’ SEC filings and other publicly available information. Based on this preliminary information, Berkeley Lights estimates that certain operations, quality and facility related costs will be reflected differently after the consummation of the transaction. This adjustment is preliminary, will change, and
could change materially depending upon the final review by Berkeley Lights after the consummation of the transaction.
|
d. |
Selling, general and administrative expenses—Adjustment to the statement of operations for total estimated remaining transaction costs of $3.5 million. Note
that a combined $9.5 million of estimated transaction costs are already included in Berkeley Lights’ and IsoPlexis’ historical audited consolidated statement of operations for the year ended December 31, 2022. Estimated
transaction costs include legal, consulting, regulatory, filing and other fees directly related to the merger.
|
e. |
Provision for income taxes—As both entities maintain full valuation allowances on their deferred tax assets, the transaction is not assumed to impact the provision for income taxes.
|
f. |
Weighted-average shares used in calculating net loss per share, basic and diluted—Reflects the pro forma issuance of 24.3 million Berkeley Lights common shares issued in exchange for outstanding shares of IsoPlexis common stock.
|
g. |
Cash and cash equivalents—Adjustment for total estimated transaction costs of $13 million, as the $9.5 million of transaction costs incurred in 2022 (see (k)
below) had not been paid as of December 31, 2022. Estimated transaction costs include legal, consulting, regulatory, filing and other fees directly related to the merger.
|
h. |
Inventory—The estimated fair value adjustment to step-up IsoPlexis’ finished goods inventory by $4.9 million.
The estimated step-up inventory will increase cost of goods sold as the acquired inventory is sold after the merger.
|
i. |
Deferred income taxes—As, among other things, both entities maintain full valuation allowances on their deferred tax assets, it is not expected that the transaction will have an impact on
deferred income taxes. This assessment could change, and change materially, when Berkeley Lights completes its acquisition accounting after the transaction closes.
|
j. |
Intangible assets, net—Represents adjustments to record the preliminary estimated fair value of intangibles of approximately $18 million, which
represents a decrease of $2 million to IsoPlexis’ net book value of intangible assets as of December 31, 2022. As the
net book value of IsoPlexis as of December 31, 2022 exceeded the estimated transaction consideration as of February 27, 2023, the Intangible assets were adjusted so that the net assets acquired and
liabilities assumed would equal the estimated transaction consideration. See Note 5 for further information. For purposes of these pro-forma financials, the capitalized licenses held by IsoPlexis are presumed to be eliminated,
with the remaining intangible asset being IsoPlexis’ patent portfolio.
|
(In thousands)
|
2023
|
2024
|
2025
|
2026
|
2027
|
|
Amortization expense
|
$1,584
|
$1,586
|
$1,508
|
$1,482
|
$1,482
|
k. |
Accrued expenses and other current liabilities — Adjustment for a combined $9.5 million of estimated transaction costs that Berkeley Lights and IsoPlexis had recorded on their historical audited consolidated balance sheets as of December 31, 2022.
|
l. |
Notes payable— Represents a $3.6 million fair value adjustment to debt obligations assumed related to deferred financing costs that will be
eliminated.
|
m. |
Total equity—Represents the elimination of IsoPlexis historical equity as well as the adjustments described above to reflect the capital structure of
the combined company.
|